| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-05-2000 |
| P698 | PubMed publication ID | 16452223 |
| P2093 | author name string | Leihua Liu | |
| Neil L Spector | |||
| Wenle Xia | |||
| Sarah Bacus | |||
| Kevin Carrick | |||
| John Bisi | |||
| Sumin Zhao | |||
| Amanda L Treece | |||
| Jay Strum | |||
| Katherine M Graham | |||
| Mary Ann Hardwicke | |||
| Michael Dush | |||
| Qiaoyin Liao | |||
| Ron E Westlund | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | overexpression | Q61643320 |
| P304 | page(s) | 1640-1647 | |
| P577 | publication date | 2006-02-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers | |
| P478 | volume | 66 |
| Q34650878 | A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer |
| Q36642955 | A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer |
| Q37690880 | An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models |
| Q39689222 | Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. |
| Q37889961 | Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer |
| Q39912369 | Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo |
| Q37947902 | Beyond trastuzumab: new treatment options for HER2-positive breast cancer |
| Q38833708 | Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation |
| Q37290504 | Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer |
| Q52578959 | Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. |
| Q36107033 | Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers |
| Q57279753 | Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL |
| Q38860383 | Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance |
| Q36603591 | Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivin |
| Q37090804 | Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice |
| Q33739267 | Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo |
| Q28283239 | Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin |
| Q24683709 | ErbB receptors: from oncogenes to targeted cancer therapies |
| Q30474678 | ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma |
| Q37072265 | ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells |
| Q37197414 | Erbb2 suppresses DNA damage-induced checkpoint activation and UV-induced mouse skin tumorigenesis |
| Q36187545 | Erbb4 Signaling: an overlooked backup system? |
| Q38525548 | Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways |
| Q34760593 | Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines |
| Q46003410 | HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors. |
| Q39620638 | HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib |
| Q36842715 | Her signaling in pancreatic cancer |
| Q36393289 | Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells |
| Q39645892 | Inhibition of ErbB2 by Herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line |
| Q53028102 | Inhibition of neointimal hyperplasia in rats treated with atorvastatin after carotid artery injury may be mainly associated with down-regulation of survivin and Fas expression. |
| Q36950485 | Inhibitor of apoptosis proteins as targets for anticancer therapy |
| Q36958613 | Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis |
| Q36440625 | Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy |
| Q37159488 | Ixabepilone: a new microtubule-targeting agent for breast cancer |
| Q36947047 | Lapatinib |
| Q37605777 | Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer |
| Q36916941 | Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer |
| Q57105786 | Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer |
| Q35624814 | Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance |
| Q37146751 | Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance |
| Q37120385 | Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis |
| Q35663802 | Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ. |
| Q37660907 | Molecular predictors of response to trastuzumab and lapatinib in breast cancer. |
| Q35783451 | Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance |
| Q57461784 | Positive feedback loop between mitochondrial fission and Notch signaling promotes survivin-mediated survival of TNBC cells |
| Q37921641 | Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer |
| Q92376425 | Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer |
| Q79976833 | Rational combinations of siRNAs targeting Plk1 with breast cancer drugs |
| Q37689286 | Recent Advances on Small-Molecule Survivin Inhibitors. |
| Q33730375 | Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies |
| Q39843650 | Regulation of Apoptosis by HER2 in Breast Cancer |
| Q35572905 | Role of traditional and new biomarkers in breast carcinogenesis. |
| Q37355370 | Role of trastuzumab in the management of HER2-positive metastatic breast cancer. |
| Q37782093 | Simultaneous targeting of estrogen receptor and HER2 in breast cancer |
| Q35770840 | Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers |
| Q37406061 | Stemming resistance to HER-2 targeted therapy |
| Q61811119 | Survivin in Insulin-Like Growth Factor-Induced Resistance to Lapatinib in Head and Neck Squamous Carcinoma Cells |
| Q37027010 | Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway |
| Q37295467 | Survivin regulation by HER2 through NF-κB and c-myc in irradiated breast cancer cells |
| Q55046676 | Survivin, cancer networks and pathway-directed drug discovery. |
| Q39727725 | Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells |
| Q52675650 | Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors. |
| Q36067934 | Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer |
| Q92619559 | The Natural-Based Antitumor Compound T21 Decreases Survivin Levels through Potent STAT3 Inhibition in Lung Cancer Models |
| Q33384289 | The UPS: a promising target for breast cancer treatment. |
| Q46157399 | The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy |
| Q55183005 | The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2. |
| Q36771985 | The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells |
| Q37063341 | The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis |
| Q37791482 | The microtubule as a breast cancer target |
| Q35667653 | The role of survivin in diagnosis, prognosis and treatment of breast cancer |
| Q37290613 | Trastuzumab in the management of early and advanced stage breast cancer. |
| Q37332545 | Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors |
| Q37539440 | mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). |
| Q34630304 | pH-responsive artemisinin derivatives and lipid nanoparticle formulations inhibit growth of breast cancer cells in vitro and induce down-regulation of HER family members |
Search more.